Rxo (RXO) EBITDA (2021 - 2026)

Rxo (RXO) has reported EBITDA for 6 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA changed N/A year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2026 stood at -$76.0 million (down 2.7% YoY), and the FY2025 full-year result was -$79.0 million, down 41.07% from the prior year.
• EBITDA advanced to $1.0 million in Q2 2026 per RXO's latest filing, from -$28.0 million in the prior quarter.
• Across five years, EBITDA topped out at $58.0 million in Q2 2022 and bottomed at -$42.0 million in Q4 2025.
• Historically, EBITDA has averaged $0.0 across 5 years, with a median of $0.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 1500.0% in 2023, then tumbled 433.33% in 2024.
• Over 5 years, EBITDA stood at -$1.0 million in 2022, then soared by 1500.0% to $14.0 million in 2023, then tumbled by 271.43% to -$24.0 million in 2024, then plunged by 75.0% to -$42.0 million in 2025, then jumped by 102.38% to $1.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $1.0 million, -$28.0 million, and -$42.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.